Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24 ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Former Stoke City players have paid tribute to club legend George Eastham at a memorial service to celebrate his ...
The school leaders taking unprecedented action to ensure a safe learning environment with amenities in good working order ...
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Norwich City will look to keep their play-off hopes alive when they welcome Stoke City to Carrow Road on Saturday afternoon ...
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...
tom's Hardware on MSN7d
TSMC and Intel rumors stoke Taiwanese fears of losing its 'Silicon Shield'When you buy through links on our articles, Future and its syndication partners may earn a commission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback